Open Access Methodology Article Optimization Algorithms for Functional Deimmunization of Therapeutic Proteins

BackgroundTo develop protein therapeutics from exogenous sources, it is necessary to mitigate the risks of eliciting an anti-biotherapeutic immune response. A key aspect of the response is the recognition and surface display by antigen-presenting cells of epitopes, short peptide fragments derived from the foreign protein. Thus, developing minimal-epitope variants represents a powerful approach to deimmunizing protein therapeutics. Critically, mutations selected to reduce immunogenicity must not interfere with the protein's therapeutic activity.ResultsThis paper develops methods to improve the likelihood of simultaneously reducing the anti-biotherapeutic immune response while maintaining therapeutic activity. A dynamic programming approach identifies optimal and near-optimal sets of conservative point mutations to minimize the occurrence of predicted T-cell epitopes in a target protein. In contrast with existing methods, those described here integrate analysis of immunogenicity and stability/activity, are broadly applicable to any protein class, guarantee global optimality, and provide sufficient flexibility for users to limit the total number of mutations and target MHC alleles of interest. The input is simply the primary amino acid sequence of the therapeutic candidate, although crystal structures and protein family sequence alignments may also be input when available. The output is a scored list of sets of point mutations predicted to reduce the protein's immunogenicity while maintaining structure and function. We demonstrate the effectiveness of our approach in a number of case study applications, showing that, in general, our best variants are predicted to be better than those produced by previous deimmunization efforts in terms of either immunogenicity or stability, or both factors.ConclusionsBy developing global optimization algorithms leveraging well-established immunogenicity and stability prediction techniques, we provide the protein engineer with a mechanism for exploring the favorable sequence space near a targeted protein therapeutic. Our mechanism not only helps identify designs more likely to be effective, but also provides insights into the interrelated implications of design choices.

[1]  S L Morrison,et al.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Robert E. Kalaba,et al.  ON THE K-TH BEST POLICIES , 1960 .

[3]  S. Henikoff,et al.  Amino acid substitution matrices from protein blocks. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Janet E. Mertz,et al.  Pre-mRNA processing enhancer (PPE) elements from intronless genes play additional roles in mRNA biogenesis than do ones from intron-containing genes , 2005, Nucleic acids research.

[5]  Bjoern Peters,et al.  Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications , 2005, Immunogenetics.

[6]  S. Stevanović,et al.  Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens. , 2001, Journal of immunological methods.

[7]  Leonard Moise,et al.  Prediction of immunogenicity for therapeutic proteins: state of the art. , 2007, Current opinion in drug discovery & development.

[8]  Dalit Naor,et al.  On Near-Optimal Alignments of Biological Sequences , 1994, J. Comput. Biol..

[9]  Benny K. C. Lo,et al.  Antibody humanization by CDR grafting. , 2004, Methods in molecular biology.

[10]  Michael S. Waterman,et al.  A dynamic programming algorithm to find all solutions in a neighborhood of the optimum , 1985 .

[11]  Thomas Pradeu,et al.  On the definition of a criterion of immunogenicity , 2006, Proceedings of the National Academy of Sciences.

[12]  Leonard G Presta,et al.  Selection, design, and engineering of therapeutic antibodies. , 2005, The Journal of allergy and clinical immunology.

[13]  Dan Gusfield,et al.  Parametric optimization of sequence alignment , 1992, SODA '92.

[14]  R. Alexander,et al.  Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from human prostatic acid phosphatase , 2007, The Prostate.

[15]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[16]  M. Lehmann,et al.  The consensus concept for thermostability engineering of proteins. , 2000, Biochimica et biophysica acta.

[17]  Huub Schellekens,et al.  Immunogenicity of therapeutic proteins: clinical implications and future prospects. , 2002, Clinical therapeutics.

[18]  Marc De Maeyer,et al.  Elimination of a Human T-cell Region in Staphylokinase by T-cell Screening and Computer Modeling , 2002, Thrombosis and Haemostasis.

[19]  Huub Schellekens,et al.  Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.

[20]  Ira Mellman,et al.  Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.

[21]  Huub Schellekens,et al.  Immunogenicity of biopharmaceuticals. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  R. Bellman,et al.  On kth Best Policies , 1960 .

[23]  Anne S De Groot,et al.  Immunogenicity of protein therapeutics. , 2007, Trends in immunology.

[24]  G. A. Lazar,et al.  A molecular immunology approach to antibody humanization and functional optimization. , 2007, Molecular immunology.

[25]  S. A. Marshall,et al.  Minimizing the immunogenicity of protein therapeutics. , 2004, Drug discovery today.

[26]  U. Şahin,et al.  Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.

[27]  Morten Nielsen,et al.  Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method , 2007, BMC Bioinformatics.

[28]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[29]  Noreen R. Gonzales,et al.  SDR grafting--a new approach to antibody humanization. , 2005, Methods.

[30]  W J Harris,et al.  Humanized antibodies. , 1993, Trends in pharmacological sciences.

[31]  E Ohage,et al.  Intrabody construction and expression. I. The critical role of VL domain stability. , 1999, Journal of molecular biology.

[32]  T. Baglin,et al.  Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII , 2005, Journal of thrombosis and haemostasis : JTH.

[33]  Anne S De Groot,et al.  Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. , 2009, Clinical immunology.

[34]  John Sidney,et al.  Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity , 2005, The Journal of Immunology.

[35]  W. Martin,et al.  De-immunization of therapeutic proteins by T-cell epitope modification. , 2005, Developments in biologicals.

[36]  John Sidney,et al.  A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..

[37]  Steve Wilson,et al.  The Immune Epitope Database and Analysis Resource: From Vision to Blueprint , 2005, PLoS biology.

[38]  Martin Lehmann,et al.  The consensus concept for thermostability engineering of proteins: further proof of concept. , 2002, Protein engineering.

[39]  L. Serrano,et al.  Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. , 2002, Journal of molecular biology.

[40]  Huub Schellekens,et al.  Factors influencing the immunogenicity of therapeutic proteins. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  Vladimir Brusic,et al.  MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides , 2005, Nucleic Acids Res..

[42]  Almer M van der Sloot,et al.  Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Fersht,et al.  Stabilization of GroEL minichaperones by core and surface mutations. , 2000, Journal of molecular biology.

[44]  Gajendra P. S. Raghava,et al.  ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..

[45]  T. Boone,et al.  Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.

[46]  A. Fersht,et al.  Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  A. Mustafa,et al.  ProPred analysis and experimental evaluation of promiscuous T-cell epitopes of three major secreted antigens of Mycobacterium tuberculosis. , 2006, Tuberculosis.

[48]  Gopi Shankar,et al.  A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs , 2007, Nature Biotechnology.

[49]  Anil K Ghosh,et al.  Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen , 2007, Proceedings of the National Academy of Sciences.

[50]  A. Mire-Sluis,et al.  Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. , 2002, Current pharmaceutical biotechnology.

[51]  François Stricher,et al.  Computer design of obligate heterodimer meganucleases allows efficient cutting of custom DNA sequences , 2008, Nucleic acids research.

[52]  Wolfgang Aehle,et al.  A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy , 2005, Molecular Cancer Therapeutics.

[53]  J. Foote,et al.  Immunogenicity of engineered antibodies. , 2005, Methods.

[54]  C. Chothia,et al.  Volume changes in protein evolution. , 1994, Journal of molecular biology.

[55]  L. Riel Table of Contents , 2010, Biological Psychiatry.

[56]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.